The combined use of lapatinib and trastuzumab (a humanized monoclonal antibody) results in synergistic antiproliferative effects in HER2-overexpressing cell lines38, and lapatinib is also useful in the treatment of trastuzumab-resistant breast cancer cells39. Here, ERBB2 is linked to breast carcinoma.